SAMSUNG BIOLOGICS CO. HAS SIGNED CMO WITH GLAXOSMITHKLINE

Highlights –

• Biopharmaceutical company Samsung Biologics Co. has signed CMO with GlaxoSmithKline.
• It has signed a deal worth $231 million.
• The contract is effective for eight years.
• Samsung Biologics will commercially produce GSK’s lupus treatment Benlysta.

South Korea’s Samsung Group on Friday announced that its biopharmaceutical business ....